Research Analysts’ Weekly Ratings Changes for Charles River Laboratories International (CRL)

A number of firms have modified their ratings and price targets on shares of Charles River Laboratories International (NYSE: CRL) recently:

• 1/23/2025 – Charles River Laboratories International had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $220.00 to $190.00. They now have a “buy” rating on the stock.
• 1/22/2025 – Charles River Laboratories International was downgraded by analysts at William Blair from an “outperform” rating to a “market perform” rating.
• 1/17/2025 – Charles River Laboratories International had its “neutral” rating reaffirmed by analysts at UBS Group AG. They now have a $185.00 price target on the stock, down previously from $250.00.
• 1/14/2025 – Charles River Laboratories International had its “outperform” rating reaffirmed by analysts at William Blair.
• 12/13/2024 – Charles River Laboratories International had its price target lowered by analysts at Bank of America Co. from $220.00 to $210.00. They now have a “neutral” rating on the stock.

Charles River Laboratories International Price Performance

CRL traded down $1.74 during trading on Friday, reaching $165.12. 441,888 shares of the company were exchanged, compared to its average volume of 995,973. The company’s 50-day moving average is $187.21 and its two-hundred day moving average is $197.51. Charles River Laboratories International, Inc. has a 12-month low of $160.85 and a 12-month high of $275.00. The company has a market cap of $8.44 billion, a price-to-earnings ratio of 20.67, a P/E/G ratio of 5.94 and a beta of 1.38. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter in the previous year, the company earned $2.72 earnings per share. Charles River Laboratories International’s revenue for the quarter was down 1.6% on a year-over-year basis. Research analysts forecast that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Charles River Laboratories International

A number of institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its stake in Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after acquiring an additional 3,738,018 shares during the last quarter. State Street Corp increased its position in shares of Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after purchasing an additional 41,421 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after buying an additional 509,163 shares in the last quarter. Earnest Partners LLC boosted its stake in Charles River Laboratories International by 12.4% in the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after buying an additional 110,725 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Charles River Laboratories International by 6.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company’s stock valued at $101,483,000 after acquiring an additional 32,311 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).